AR024232A1 - Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion - Google Patents
Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacionInfo
- Publication number
- AR024232A1 AR024232A1 ARP990106025A ARP990106025A AR024232A1 AR 024232 A1 AR024232 A1 AR 024232A1 AR P990106025 A ARP990106025 A AR P990106025A AR P990106025 A ARP990106025 A AR P990106025A AR 024232 A1 AR024232 A1 AR 024232A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- eletriptan
- monohidratado
- bromhydrate
- medicines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Electroluminescent Light Sources (AREA)
- Lasers (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Bromhidrato de eletriptán monohidrato de formula (1) junto con procedimientos para preparar dicho monohidrato, usos del mismo y composiciones que locontienen. El eletriptán, éste clasificado agonista del receptor 5-HT IB ID y en particular utilidad en el tratamiento de migrana y en la prevencion de larecurrencia de la migrana.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9825988.0A GB9825988D0 (en) | 1998-11-27 | 1998-11-27 | Indole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024232A1 true AR024232A1 (es) | 2002-09-25 |
Family
ID=10843140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106025A AR024232A1 (es) | 1998-11-27 | 1999-11-25 | Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion |
Country Status (53)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0018968D0 (en) * | 2000-08-02 | 2000-09-20 | Pfizer Ltd | Particulate composition |
| JP2006522790A (ja) | 2003-04-11 | 2006-10-05 | ファイザー・インク | エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物 |
| GB0317229D0 (en) * | 2003-07-23 | 2003-08-27 | Pfizer Ltd | Improved process |
| US6927296B2 (en) | 2003-07-23 | 2005-08-09 | Pfizer Inc. | Process |
| EP2093224A1 (en) | 2007-05-01 | 2009-08-26 | Plus Chemicals B.V. | Process for preparing eletriptan hydrobromide form beta |
| EP2038273A1 (en) * | 2007-05-29 | 2009-03-25 | Plus Chemicals B.V. | A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole |
| US20100285075A1 (en) * | 2007-12-17 | 2010-11-11 | Actavis Group Ptc Ehf | Novel Hemioxalate Salt of Eletriptan |
| WO2010097703A1 (en) * | 2009-02-25 | 2010-09-02 | Actavis Group Ptc Ehf | Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity |
| WO2010116386A2 (en) * | 2009-04-08 | 2010-10-14 | Biophore India Pharmaceuticals Pvt. Ltd. | Novel polymorph of eletriptan hydrobromide and process for the preparation thereof |
| WO2011089614A1 (en) * | 2010-01-19 | 2011-07-28 | Sms Pharmaceuticals Limited | PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM |
| WO2014063752A1 (en) | 2012-10-26 | 2014-05-01 | Synthon Bv | Process for making crystalline form alpha of eletriptan hydrobromide |
| CN103893112A (zh) * | 2012-12-31 | 2014-07-02 | 重庆圣华曦药业股份有限公司 | 氢溴酸依来曲普坦注射液 |
| CN107954947A (zh) * | 2016-10-14 | 2018-04-24 | 北京莱瑞森医药科技有限公司 | 沃替西汀氢溴酸盐晶型c及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3952741A (en) * | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
| FR2624732B1 (fr) * | 1987-12-21 | 1991-02-15 | Synthelabo | Formulation pharmaceutique a liberation prolongee |
| US5474784A (en) * | 1990-03-02 | 1995-12-12 | British Technology Group Limited | Dispensing device |
| HU225055B1 (en) | 1990-10-15 | 2006-05-29 | Pfizer | Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds |
| US5545644A (en) * | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| US5464633A (en) * | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
| GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
| GB9510223D0 (en) * | 1995-05-20 | 1995-07-19 | Pfizer Ltd | Therapeutic agent |
| TW448172B (en) * | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
| US5998462A (en) * | 1996-12-16 | 1999-12-07 | Allelix Biopharmaceuticals Inc. | 5-alkyl indole compounds |
| GB9704498D0 (en) * | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Chemical compound |
| ES2163291T3 (es) | 1997-07-03 | 2002-01-16 | Pfizer | Composiciones farmaceuticas que contienen eletriptan hemisulfato y cafeina. |
-
1998
- 1998-11-27 GB GBGB9825988.0A patent/GB9825988D0/en not_active Ceased
-
1999
- 1999-01-11 UA UA2001053569A patent/UA68402C2/uk unknown
- 1999-11-01 NZ NZ510055A patent/NZ510055A/en unknown
- 1999-11-01 GE GEAP19995913A patent/GEP20043183B/en unknown
- 1999-11-01 SK SK699-2001A patent/SK285774B6/sk unknown
- 1999-11-01 ID IDW00200101132A patent/ID28802A/id unknown
- 1999-11-01 AU AU62253/99A patent/AU754731B2/en not_active Ceased
- 1999-11-01 OA OA1200100103A patent/OA11671A/en unknown
- 1999-11-01 EE EEP200100285A patent/EE04914B1/xx not_active IP Right Cessation
- 1999-11-01 CZ CZ20011839A patent/CZ295472B6/cs not_active IP Right Cessation
- 1999-11-01 IL IL14166399A patent/IL141663A/en not_active IP Right Cessation
- 1999-11-01 ES ES99949292T patent/ES2224701T3/es not_active Expired - Lifetime
- 1999-11-01 EP EP99949292A patent/EP1135381B1/en not_active Expired - Lifetime
- 1999-11-01 JP JP2000585231A patent/JP3777094B2/ja not_active Expired - Fee Related
- 1999-11-01 AP APAP/P/2001/002149A patent/AP2001002149A0/en unknown
- 1999-11-01 CN CN998135798A patent/CN1131860C/zh not_active Expired - Fee Related
- 1999-11-01 HU HU0105308A patent/HUP0105308A3/hu unknown
- 1999-11-01 BR BR9915692-0A patent/BR9915692A/pt not_active Application Discontinuation
- 1999-11-01 CA CA002352392A patent/CA2352392C/en not_active Expired - Fee Related
- 1999-11-01 WO PCT/IB1999/001754 patent/WO2000032589A1/en active IP Right Grant
- 1999-11-01 KR KR10-2001-7006605A patent/KR100413739B1/ko not_active IP Right Cessation
- 1999-11-01 RS YUP-188/01A patent/RS50002B/sr unknown
- 1999-11-01 PT PT99949292T patent/PT1135381E/pt unknown
- 1999-11-01 DE DE69919388T patent/DE69919388T2/de not_active Expired - Fee Related
- 1999-11-01 EA EA200100297A patent/EA003551B1/ru not_active IP Right Cessation
- 1999-11-01 PL PL99347928A patent/PL194503B1/pl unknown
- 1999-11-01 AT AT99949292T patent/ATE273300T1/de not_active IP Right Cessation
- 1999-11-01 DK DK99949292T patent/DK1135381T3/da active
- 1999-11-01 SI SI9930633T patent/SI1135381T1/xx unknown
- 1999-11-01 TR TR2001/01493T patent/TR200101493T2/xx unknown
- 1999-11-02 TW TW088119069A patent/TWI246512B/zh not_active IP Right Cessation
- 1999-11-09 HN HN1999000196A patent/HN1999000196A/es unknown
- 1999-11-18 PA PA19998485701A patent/PA8485701A1/es unknown
- 1999-11-23 PE PE1999001178A patent/PE20001299A1/es not_active Application Discontinuation
- 1999-11-24 DZ DZ990248A patent/DZ2948A1/xx active
- 1999-11-24 TN TNTNSN99221A patent/TNSN99221A1/fr unknown
- 1999-11-24 CO CO99074057A patent/CO5150178A1/es unknown
- 1999-11-24 GC GCP1999381 patent/GC0000113A/xx active
- 1999-11-24 MA MA25854A patent/MA26708A1/fr unknown
- 1999-11-25 AR ARP990106025A patent/AR024232A1/es not_active Application Discontinuation
- 1999-11-25 MY MYPI99005153A patent/MY124078A/en unknown
- 1999-11-26 SV SV1999000204A patent/SV1999000204A/es not_active Application Discontinuation
- 1999-11-26 GT GT199900202A patent/GT199900202A/es unknown
- 1999-11-29 US US09/450,462 patent/US20020013358A1/en not_active Abandoned
- 1999-11-29 UY UY25823A patent/UY25823A1/es unknown
- 1999-11-30 UY UY25825A patent/UY25825A1/es unknown
-
2001
- 2001-02-27 IS IS5868A patent/IS2238B/is unknown
- 2001-03-13 CU CU20010065A patent/CU23269A3/es unknown
- 2001-03-14 CR CR6325A patent/CR6325A/xx not_active Application Discontinuation
- 2001-04-02 ZA ZA200102681A patent/ZA200102681B/xx unknown
- 2001-05-23 BG BG105539A patent/BG64706B1/bg unknown
- 2001-05-24 HR HR20010398 patent/HRP20010398B1/xx not_active IP Right Cessation
- 2001-05-25 NO NO20012584A patent/NO320798B1/no unknown
-
2002
- 2002-06-11 HK HK02104379.1A patent/HK1042898B/zh not_active IP Right Cessation
-
2003
- 2003-02-27 US US10/376,385 patent/US7238723B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25794A1 (es) | Procedimiento para la preparacion de compuestos derivados de adeninas, que son agonistas del receptor de la adenosina a2a | |
| HN2002000275A (es) | Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados | |
| BR0314356A (pt) | Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas | |
| AR024138A1 (es) | Inhibidores de la proliferacion celular | |
| AR024232A1 (es) | Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion | |
| UY28342A1 (es) | Nuevos compuestos | |
| MX9803792A (es) | Inhibidor de proteina cinasa c. | |
| ATE293995T1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| HUP0104696A2 (hu) | 5HT1 receptor agonistákat és metoklopramidot tartalmazó gyógyszerkészítmény migrén kezelésére | |
| BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
| CY1105953T1 (el) | Συνθεσεις για απελευθερωση συνδυασμων φαρμακων | |
| CA2378428A1 (en) | Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes | |
| YU13301A (sh) | Muskarinski agonisti i antagonisti | |
| CL43546B (es) | Compuesto derivado de tetrahidroquinolina con actividad moduladora del receptor fsh; composicion farmaceutica que contiene al compuesto; y uso del compuesto en la preparacion de medicamentos para la regulacion de la fertilidad. | |
| AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
| CO5190664A1 (es) | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 | |
| UY27753A1 (es) | Formulación farmacéutica que comprende melatonina. | |
| CL2002001701A1 (es) | Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno. | |
| BR0015172A (pt) | Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno | |
| NO983177L (no) | Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft | |
| EA200201149A1 (ru) | Фармацевтические композиции и способы для предотвращения рецидива мигрени | |
| ES2175661T3 (es) | Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| HUP0001888A2 (hu) | 5HT1 Agonistát és COX-2 inhibitort vagy NSAID-t tartalmazó gyógyszerészeti összetétel migrén kezelésére | |
| WO1999045905A3 (en) | Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |